Welcome!

News Feed Item

Nasal Drug Delivery - Advances in Drug Therapies, Systemic Delivery and Device Technologies (Conference, London)

DUBLIN, March 13, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/jdzmv4/nasal_drug) have announced the addition of the "Nasal Drug Delivery - Advances in Drug Therapies, Systemic Delivery and Device Technologies (Conference, London)" conference to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The Nasal Drug Delivery Conference will take place on the 3rd & 4th April 2014 at the Rembrandt Hotel, London

THREE REASONS TO ATTEND THIS EVENT

- Gain an update on the very latest scientific developments and technology advances in this field.

- Hear from an unrivaled panel of expert speakers.

- An excellent networking opportunity to build business relationships.

WHO SHOULD ATTEND

Managing Directors, Medical Directors, Head of Regulatory Affairs and Quality Assurance, Senior Executives in Research and Development, Registration, Marketing and all departments that may be involved in Nasal Drug Delivery, or who wish to understand the potential of this alternative therapeutic route. Those already involved in Nasal Drug Delivery will benefit from updating their knowledge and sharing experiences with some of the leading practitioners in this field. If you are involved in Nasal Drug Delivery or are just considering the potential, this conference is an excellent route to understanding all aspects from the basic physiology through to launching a successful product. 

CHAIRPERSON: Dr Rene Bommer

KEYNOTE SPEAKER: Prof. Michael S Benninger

DATES:

3 & 4 April 2014

TIMES:

3 April 2014: Start 09.30 - Finish 17.30
Drinks Reception: Start 17.30 - Finish 18.30
4 April 2014: Start 09.15 - Finish 16.30

REGISTRATION & COFFEE

3 April 2014 09.00

VENUE & ACCOMMODATION

The Rembrandt Hotel, 11 Thurloe Place, London SW7 2RS

DIRECTIONS:

Opposite V&A Museum. Nearest underground station: South Kensington.

NOTE: Events may be cancelled due to commercial or organisational reasons. In this case Research and Markets will refund all registration fees which have already been paid. Research and Markets will not refund any charges arising from the participant having to cancel or re-book transportation or accommodation which he or she has arranged 

Key Topics Covered: 

DAY ONE - 3 April 2014

09.30 u Chairman's Welcome and Introduction
Dr René Bommer, Director, pharmAccel Consulting, Germany 

Session 1: Advances in Drug Therapies: State of the Art

09.45 u Nasal Drugs to Treat Nasal Disorders; A Comprehensive Review

- Anatomy and physiology
- Nasal disorders
- Treatment options and future prospects to treat allergic and non-allergic Rhinitis
- Rhinosinusitis and Polyps

Professor Michael S. Benninger, Chairman, The Head and Neck Institute, Professor of Surgery, Lerner College of Medicine, The Cleveland Clinic, USA 

10.45 - Discussion 

11.00 - Coffee

Session 2: Progress in Local and Systemic Nasal Drug Delivery

11.30 - Particulate Systems for Nasal (Vaccine) Delivery

- Literature review on particulate systems for nasal delivery
- Nanoparticulate systems for direct uptake
- Particle requirements for nasal deposition
- Modification of particle surface/particle engineering
- Formulation design
- Implications in nasal vaccine development

Dr Regina Scherliess, Christian Albrecht University of Kiel, Department of Pharmaceutics and Biopharmaceutics, Germany

12.10 - Antiviral Polymers - A Novel Concept of Intranasal Therapy Against Respiratory Viruses

- Marinomed has developed a technology for creating a protective physical barrier in the nasal cavity with antiviral polymers for the prevention and therapy of common cold and influenza

- Independent clinical trials in adults and children demonstrated that the intranasal administration of Iota-Carrageenan significantly reduced the time to disease clearance of patients with common cold and decreased the virus load in nasal lavages

- The existing product portfolio will be expanded and the new developments focus on combination products for the treatment of influenza and the prevention of virally-induced exacerbations in allergic patients 

Dr Angelika Bodenteich, Head of Development, Marinomed Biotechnologie, GmbH, Germany

12.50 - Discussion

13.00 - Lunch

14.00 - Nasal Drug Delivery - The Technology Whose Potential Has Not Yet Been Valorised

- Current technologies for nasal drug delivery
- Nasal application for unmet medical needs
- Factors affecting bioavailability and response after nasal application
- Symbiosis of formulation and device
- Identification of potential obstacles in product development

Dr Claudia Mattern, Adjunct Professor Nova Southeastern University, US-FL, Chief Scientific Officer, M & P Pharma AG, Switzerland 

Session 3: Nasal Devices, Device Testing and New Technologies

14.40 - Review of Nasal Drug Delivery Devices

- Business aspects
- Device technologies and nasal delivery systems
- Regulatory aspects
- Nasl spray characterisation 

Dr René Bommer, Director, pharmAccel Consulting, Germany 

15.20 - Discussion 

15.30 - Tea

16.00 - New Trends in Nasal Delivery with Dry Powder Formulations

- Dry powder formulations represent attractive alternatives to liquid formulations

- Systemic delivery via the nasal cavity, including pain treatments and also intra-nasal vaccination, are being investigated and developed with dry powder formulation because it offers a number of benefits like thermal and microbiologic stability and the variability of the physico-chemical properties

- Regulatory Aptar pharma offers a line of disposable primeless devices designed specifically for liquid and for dry powder formulations

- Opportunities and case studies using our Unit Dose Powder, Single Dose Device technology platform

Holger Kehrer, Business Support Manager, Aptar pharma, France 

16.40 - Update on Advancia: Innovative Design Solution to Respond to New Challenges in Nasal Delivery

- Recent trends in nasal spray delivery
- Compliance, efficiency, convenience and ease of use of nasal delivery devices
- Regulatory requirement changes for nasal delivery requiring next generation devices

Pascale Farjas, Global Category Manager, Rexam Healthcare, France 

17.20 - Discussion 

17.30 - Close of Day One

17.30 - 18.30 Drinks Reception for Delegates and Speakers

DAY TWO - 4 April 2014

09.15 - Chairman's Review of Day One 

Dr René Bommer, Director, pharmAccel Consulting, Germany 

Session 4: Nasal Devices, Device Testing and New Technologies (continued)

09.30 - Current Nasal Powder Technologies: The Challenge of Powder Dosing

- Dosing requirements (dosing range, target to be filled, powder properties)
- Overview dosing systems (design, functionality)
- Examples of filling equipment (developmental equipment)
- Systems for fill weight verification (IPC, PAT,..)

Marco Laackmann, Division Leader, Inhalation, Harro Höfliger, Germany 

10.10 - Addressing Technical Barriers in Nasal Dry Powder Delivery 

- Patient / user needs - clinical trials, comfort, understanding
- Device requirements - materials, regulatory, risks
- Formulation requirements - dosage, residence time, stability
- Product performance - deposition, particle size distribution, plume geometry, shelf life
- Commercialisation - competition, cost, IP, market need, regulatory acceptance, USP

Ian Harrison, Chief Scientific Officer, Alchemy Pharmatech, UK 

10.50 - Discussion

11.00 - Coffee

11.30 - How Technology Can be Used to Enhance our Understanding of User Behaviour and Influence the Way we Conduct User Research

- Social Intelligence for greater product understanding
- Gaining access to the right study participants
- Field research from your desk
- Quantifying human performance
- Seeing through our users eyes
- Understanding emotional responses and states of mind

Miranda Newberry, Human Factors Consultant, PA Consulting, UK

12.10 - A Platform Approach to Developing Patient Oriented Drug Delivery Systems and Products

- This approach to the development of drug delivery technology solutions is unconventional, risky and offers tremendous potential for developing drug/device combination products that deliver unparalleled value to both the patient and the manufacturer

- This well-executed platform based approach seeks to reduce the complexity of developing new combination products without sacrificing innovation

- Progress of Mystic's drug delivery platform solutions, its capabilities, applications and the benefits for patients and Pharma/biotech manufacturers
Timothy Sullivan, President & CEO, Mystic Pharmaceuticals Inc., USA (invited)

12.50 - Discussion

13.00 - Lunch

Session 5: Regulatory Requirements

14.00 - EU Regulatory Requirements 

- Differences between pulmonary and nasal requirements
- Bio-equivalence Representative from a Regulatory Agency, (invited)

14.40 - Discussion

Session 6: Business and Intellectual Property (IP) in Nasal Systemic Drug Delivery

14.50 - Choosing the Best Way to Finance Your Company 

- First: get the business model right
- Starting out - is there easy money?
- Angels vs Dragons
- Dilutive vs non-dilutive financing
- Financing through partnering
- Planning an exit - IPO vs Trade Sale

Finton Walton, CEO, Pharma Ventures, UK

15.30 - R&D Collaborations for Drug Delivery: Legal and Contractual Issues

- The different priorities of universities, start-ups and major companies
- Benefits of term sheets / letters of intent and how to use them
- Defining the scope of the collaboration: work, field, etc.
- IP ownership and licences
- Other legal issues

Mark Anderson, Solicitor, Anderson Law LLP, UK

16.10 u Discussion

16.20 u Chairman's Concluding Remarks

16.30 u Close of Conference and Tea 

For more information visit http://www.researchandmarkets.com/research/jdzmv4/nasal_drug

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Cell networks have the advantage of long-range communications, reaching an estimated 90% of the world. But cell networks such as 2G, 3G and LTE consume lots of power and were designed for connecting people. They are not optimized for low- or battery-powered devices or for IoT applications with infrequently transmitted data. Cell IoT modules that support narrow-band IoT and 4G cell networks will enable cell connectivity, device management, and app enablement for low-power wide-area network IoT. B...
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
"DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great team at @DevOpsSUMMIT and CloudEXPO tell the world how they can leverage this emerging disruptive trend."
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
Transformation Abstract Encryption and privacy in the cloud is a daunting yet essential task for both security practitioners and application developers, especially as applications continue moving to the cloud at an exponential rate. What are some best practices and processes for enterprises to follow that balance both security and ease of use requirements? What technologies are available to empower enterprises with code, data and key protection from cloud providers, system administrators, inside...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and Bi...
Nicolas Fierro is CEO of MIMIR Blockchain Solutions. He is a programmer, technologist, and operations dev who has worked with Ethereum and blockchain since 2014. His knowledge in blockchain dates to when he performed dev ops services to the Ethereum Foundation as one the privileged few developers to work with the original core team in Switzerland.
Contextual Analytics of various threat data provides a deeper understanding of a given threat and enables identification of unknown threat vectors. In his session at @ThingsExpo, David Dufour, Head of Security Architecture, IoT, Webroot, Inc., discussed how through the use of Big Data analytics and deep data correlation across different threat types, it is possible to gain a better understanding of where, how and to what level of danger a malicious actor poses to an organization, and to determin...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
Digital Transformation and Disruption, Amazon Style - What You Can Learn. Chris Kocher is a co-founder of Grey Heron, a management and strategic marketing consulting firm. He has 25+ years in both strategic and hands-on operating experience helping executives and investors build revenues and shareholder value. He has consulted with over 130 companies on innovating with new business models, product strategies and monetization. Chris has held management positions at HP and Symantec in addition to ...
Traditional IT, great for stable systems of record, is struggling to cope with newer, agile systems of engagement requirements coming straight from the business. In his session at 18th Cloud Expo, William Morrish, General Manager of Product Sales at Interoute, will outline ways of exploiting new architectures to enable both systems and building them to support your existing platforms, with an eye for the future. Technologies such as Docker and the hyper-convergence of computing, networking and...